Kastia

Rosuvastatin, the active ingredient in Kastia, is a HMG‑CoA reductase inhibitor presented as an oral tablet for oral use. It lowers elevated cholesterol and triglyceride levels and is used to reduce cardiovascular risk in patients with hypercholesterolemia or mixed dyslipidaemia.

GNH USA supplies Kastia as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Rosuvastatin is indicated for disorders of lipid metabolism and for reducing cardiovascular events in at‑risk populations.

- Hypercholesterolemia: lowers low‑density lipoprotein (LDL) cholesterol to target levels. - Hyperlipidemia: reduces total cholesterol, LDL‑C and triglycerides while modestly increasing HDL‑C. - Prevention of cardiovascular events in at‑risk patients: decreases the incidence of myocardial infarction, stroke and revascularisation procedures.

Rosuvastatin may cause a range of adverse reactions, most of which are dose‑related and reversible upon discontinuation.

Common Side Effects: - Headache: mild to moderate intensity. - Myalgia: muscle aches without weakness. - Nausea: occasional gastrointestinal upset. - Abdominal discomfort: mild stomach pain or cramping. - Elevated liver enzymes: transient increase in ALT/AST. - Dizziness: occasional light‑headed sensation.

Serious or Rare Side Effects: - Rhabdomyolysis: severe muscle breakdown with dark urine. - Hepatotoxicity: significant rise in liver transaminases or jaundice. - Acute renal failure: sudden decrease in kidney function. - Allergic reactions: rash, pruritus or angioedema.

Rosuvastatin should be used with caution in specific clinical situations and according to professional guidelines.

- Assess liver function: obtain baseline ALT/AST before initiating therapy. - Monitor renal function: adjust dose in patients with moderate to severe renal impairment. - Evaluate for muscle symptoms: discontinue if unexplained muscle pain or weakness occurs. - Avoid use in pregnancy and lactation: safety not established. - Store at ambient temperature: keep below 25 °C, in the original packaging, protected from moisture and light.

Rosuvastatin may interact with several concomitant medications, altering its efficacy or safety profile.

Major Interactions (Avoid): - Cyclosporine: markedly increases rosuvastatin plasma concentrations. - Strong CYP2C9 inhibitors (e.g., fluconazole): may raise exposure and risk of toxicity.

Moderate Interactions (Monitor Closely): - Anticoagulants (warfarin): may enhance anticoagulant effect, requiring INR monitoring. - Fibrates (gemfibrozil): increase risk of myopathy. - Antacids containing aluminium or magnesium: may reduce rosuvastatin absorption if taken simultaneously.